AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25369174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23135095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (SO) or Sunitinib (SU)
Number of subjects: 23
Study 19907160 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (usual MAP goal)
Number of subjects: 164
Study 19907160 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (lower MAP goal)
Number of subjects: 164
Study 19907160 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 A6986G
Number of subjects: 164
Study 18565338 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision with primary closure and drainage (group A)
Number of subjects: 103
Study 18565338 — intervention group
Group type: COMPARATOR
Intervention: Excision with primary closure without drainage (group B)
Number of subjects: 103
Study 15756351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology (FNAC)
Number of subjects: 296
Study 15756351 — intervention group
Group type: COMPARATOR
Intervention: Core Needle Biopsy (CNB)
Number of subjects: 296
Study 12703665 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HIV prevention protocol
Number of subjects: 1728
Study 12703665 — intervention group
Group type: COMPARATOR
Intervention: Enhanced HIV prevention protocol
Number of subjects: 1728
Study 10485773 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging stylet intubation
Number of subjects: 0
Study 10485773 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 0
Study 10485773 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic bronchoscopy
Number of subjects: 0
Study 9139276 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after biliary acute pancreatitis (AP)
Number of subjects: 40
Study 9139276 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis (ChP) with normal carbohydrate tolerance
Number of subjects: 40
Study 9139276 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis and impaired glucose tolerance (ChP + IGT)
Number of subjects: 40
Study 9139276 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study 1931065 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental sodium 1.5 mg/kg IV
Number of subjects: 30
Study 1931065 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg IV
Number of subjects: 30
Study 1931065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for 3.5 minutes)
Number of subjects: 30
Study 6849167 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 17
Study 6849167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31226435 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (3 g)
Number of subjects: 22
Study 31226435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g of starch)
Number of subjects: 22
Study 31226435 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity physical training (Deep Water Running for 8 weeks, 3 times/week, 50 min/session at 70-85% maximum heart rate)
Number of subjects: 22
Study 30314452 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years
Number of subjects: 30848
Study 30314452 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM 5y - AI 5y treatment
Number of subjects: 30848
Study 30314452 — intervention group
Group type: EXPERIMENTAL
Intervention: (AI and/or TAM) 5y - LET 5y treatment
Number of subjects: 30848
Study 30314452 — intervention group
Group type: COMPARATOR
Intervention: TAM 5y - TAM 5y treatment
Number of subjects: 30848
Study 30314452 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years in lymph node-positive subgroup
Number of subjects: 30848
Study 30314452 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years in postmenopausal subgroup
Number of subjects: 30848
Study 30314452 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years in ER+ and/or PR+ subgroup
Number of subjects: 30848
Study 25831994 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional gender role attitudes at T1
Number of subjects: 577
Study 25831994 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms and gender role attitudes
Number of subjects: 577
Study 25831994 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneously targeting injunctive norms and gender role attitudes
Number of subjects: 577
Study 25260948 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal myectomy
Number of subjects: 25
Study 23327033 — intervention group
Group type: COMPARATOR
Intervention: Esmolol infusion
Number of subjects: 20
Study 23327033 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 infusion
Number of subjects: 20
Study 20350344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplemented parenteral nutrition (PN)
Number of subjects: 27
Study 20350344 — intervention group
Group type: COMPARATOR
Intervention: Standard olive oil (OO) emulsion
Number of subjects: 27
Study 19104986 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day momentary assessment protocol of pain and fatigue
Number of subjects: 105
Study 16129793 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter-wire group
Number of subjects: 200
Study 16129793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 12375752 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 104
Study 12375752 — intervention group
Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 104
Study 10474757 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1000 mg/m2 or more)
Number of subjects: 0
Study 10474757 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with cisplatin
Number of subjects: 0
Study 10474757 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin-vinorelbine
Number of subjects: 0
Study 10474757 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin
Number of subjects: 0
Study 8866910 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multiple risk factor modification programme
Number of subjects: 508
Study 8866910 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study 1983321 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg o.m.)
Number of subjects: 98
Study 1983321 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg b.d.)
Number of subjects: 98
Study 7025257 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 8
Study 7025257 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 8
Study 30391468 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up approach
Number of subjects: 73
Study 30391468 — intervention group
Group type: COMPARATOR
Intervention: Open necrosectomy
Number of subjects: 73
Study 28340570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-C5 vaccine administered intramuscularly with Alhydrogel or intradermally with GM-CSF as adjuvant
Number of subjects: 36
Study 28340570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-C5 vaccine
Number of subjects: 36
Study 24025012 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor tenotomy
Number of subjects: 155
Study 24025012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adductor tenotomy and hernioplasty
Number of subjects: 155
Study 21872212 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of AVSD
Number of subjects: 215
Study 19017864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nasal continuous positive airway pressure (nCPAP) at 10 cm H(2)O for at least 6 hours
Number of subjects: 500
Study 19017864 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment including 10 min of intermittent nCPAP at 10 cm H(2)O every 4 hours
Number of subjects: 500
Study 19017864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nasal continuous positive airway pressure (nCPAP)
Number of subjects: 500
Study 19017864 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 500
Study 17237648 — intervention group
Group type: COMPARATOR
Intervention: Conventional MUF (group C)
Number of subjects: 80
Study 17237648 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow rate MUF (group H)
Number of subjects: 80
Study 17237648 — intervention group
Group type: EXPERIMENTAL
Intervention: High negative pressure MUF (group P)
Number of subjects: 80
Study 17237648 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration, high flow rate MUF (group L)
Number of subjects: 80
Study 14725516 — intervention group
Group type: EXPERIMENTAL
Intervention: Synacthen Depot 1 mg (1 ml)
Number of subjects: 18
Study 14725516 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline 1 ml
Number of subjects: 18
Study 11467465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker telemetry
Number of subjects: 18
Study 11467465 — intervention group
Group type: COMPARATOR
Intervention: Holter recordings
Number of subjects: 18
Study 9720545 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical urethral anesthesia
Number of subjects: 45
Study 9720545 — intervention group
Group type: COMPARATOR
Intervention: Topical urethral anesthesia with adjunctive intravenous sedoanalgesia
Number of subjects: 45
Study 9720545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Topical anesthesia and Sedoanalgesia)
Number of subjects: 45
Study 8158032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine prophylaxis (10 mg/kg initial loading dose)
Number of subjects: 339
Study 8158032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine prophylaxis
Number of subjects: 339
Study 8158032 — intervention group
Group type: COMPARATOR
Intervention: Falciparum malaria
Number of subjects: 339
Study 8158032 — intervention group
Group type: COMPARATOR
Intervention: Maternal anemia at delivery (hematocrit < 30%)
Number of subjects: 339
Study 3377147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 2 mg/kg
Number of subjects: 60
Study 3377147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular papaveretum 0.2 mg/kg
Number of subjects: 60
Study 3377147 — intervention group
Group type: COMPARATOR
Intervention: No medication (placebo)
Number of subjects: 60
Study 31131641 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported group (physiotherapist-supported individualised activity programme)
Number of subjects: 30
Study 31131641 — intervention group
Group type: COMPARATOR
Intervention: Unsupported group (free choice, control)
Number of subjects: 30
Study 29553862 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV SC
Number of subjects: 722
Study 29553862 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV IM
Number of subjects: 722
Study 29553862 — intervention group
Group type: COMPARATOR
Intervention: Heptavax®‐II SC
Number of subjects: 722
Study 27893482 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Vest (WV)
Number of subjects: 19
Study 27893482 — intervention group
Group type: COMPARATOR
Intervention: Unresisted Sprint (US)
Number of subjects: 19
Study 26679936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the right DLPFC
Number of subjects: 36
Study 26679936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left DLPFC
Number of subjects: 36
Study 26679936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left DLPFC
Number of subjects: 36
Study 26679936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the right DLPFC
Number of subjects: 36
Study 26679936 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study 23446073 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based cognitive-behavioral treatment (BFB-CBT)
Number of subjects: 58
Study 23446073 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint (OS)
Number of subjects: 58
Study 22010417 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin for 7 days
Number of subjects: 32
Study 22010417 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study 18398800 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 0
Study 18398800 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 18398800 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 0
Study 17353630 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) every three weeks (TC) for 4 cycles
Number of subjects: 8
Study 17353630 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) every three weeks (TC) for 8 cycles
Number of subjects: 8
Study 14576955 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 4875
Study 14576955 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 4875
Study 11507921 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental triclosan-containing dentifrice
Number of subjects: 0
Study 11507921 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice
Number of subjects: 0
Study 9773111 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 0
Study 9773111 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (300 mg)
Number of subjects: 0
Study 8196120 — intervention group
Group type: EXPERIMENTAL
Intervention: OspA Lyme vaccine (10 micrograms, 2 doses)
Number of subjects: 36
Study 8196120 — intervention group
Group type: EXPERIMENTAL
Intervention: OspA Lyme vaccine adsorbed to alum (10 micrograms, 2 doses)
Number of subjects: 36
Study 8196120 — intervention group
Group type: COMPARATOR
Intervention: Buffer placebo
Number of subjects: 36
Study 3281563 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal disconnection of the esophagus with a clip (surgical group)
Number of subjects: 100
Study 3281563 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control group)
Number of subjects: 100
Study 31690121 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with 1% lidocaine and epinephrine (1 mL, 40 mg triamcinolone + 1 mL lidocaine with epinephrine)
Number of subjects: 73
Study 31690121 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection with normal saline (1 mL, 40 mg triamcinolone + 1 mL normal saline)
Number of subjects: 73
Study 30199771 — intervention group
Group type: EXPERIMENTAL
Intervention: Online expanded Body Project (n=46)
Number of subjects: 82
Study 30199771 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition (n=36)
Number of subjects: 82
Study 27106967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 4 g over 1 h, then 1 g per h over six h
Number of subjects: 0
Study 27106967 — intervention group
Group type: COMPARATOR
Intervention: Control group (H)
Number of subjects: 0
Study 27106967 — intervention group
Group type: COMPARATOR
Intervention: Non-haemorrhagic group (NH)
Number of subjects: 0
Study 24504445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 45 mg/m² every 4 weeks
Number of subjects: 78
Study 24504445 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1000 mg/m² twice daily, day 1-14 every 3 weeks
Number of subjects: 78
Study 22776045 — intervention group
Group type: EXPERIMENTAL
Intervention: CC with a bolus calculator
Number of subjects: 40
Study 22776045 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual CC
Number of subjects: 40
Study 22776045 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional dietary education)
Number of subjects: 40
Study 22776045 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 20660038 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg cosyntropin test
Number of subjects: 56
Study 20660038 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 56
Study 18486512 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alanine aminotransferase (ALT) levels of 17-22 mg/dl
Number of subjects: 3989
Study 18486512 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alanine aminotransferase (ALT) levels of 23-38 mg/dl
Number of subjects: 3989
Study 18486512 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alanine aminotransferase (ALT) levels greater than 38 mg/dl
Number of subjects: 3989
Study 18486512 — intervention group
Group type: COMPARATOR
Intervention: Baseline alanine aminotransferase (ALT) levels
Number of subjects: 3989
Study 16133900 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SPORT (brief consultation and prescription with a mailed reinforcing follow-up flyer)
Number of subjects: 604
Study 16133900 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control (wellness brochure and pamphlet about teen health and fitness)
Number of subjects: 604
Study 12471182 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (2 mg/2 mL) administered into the lumen of the central venous catheter, with a maximum of two doses allowed to dwell for up to 120 minutes each.
Number of subjects: 1064
Study 9972770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 9972770 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 9972770 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 7593523 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist administration
Number of subjects: 0
Study 7593523 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophins
Number of subjects: 0
Study 7593523 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone secretion
Number of subjects: 0
Study 7593523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance index > 0.79 before HMG commencement
Number of subjects: 0
Study 7593523 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RI value 2 days before HMG commencement
Number of subjects: 0
Study 7593523 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy rates
Number of subjects: 0
Study 2106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 4 mg i.v. administered 3 h before GHRH
Number of subjects: 34
Study 2106087 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 34
Study 2106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 8 mg p.o. administered 12 h before GHRH
Number of subjects: 34
Study 2106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 22 mg p.o. over 2 days before GHRH
Number of subjects: 34
Study 2106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine administration 300 micrograms p.o. with Dex 4 mg i.v. given 3 h before
Number of subjects: 34
Study 2106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine administration 300 micrograms p.o. with Dex 8 mg
Number of subjects: 34
Study 2106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine administration 300 micrograms p.o. with Dex 22 mg
Number of subjects: 34
Study 388678 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 195
Study 388678 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 195
Study 388678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 31375659 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 214
Study 31375659 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 214
Study 31375659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 27470507 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual unenhanced (VUE) images
Number of subjects: 94
Study 26115866 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly crosslinked-remelted polyethylene (HXLPE)
Number of subjects: 171
Study 26115866 — intervention group
Group type: COMPARATOR
Intervention: Less-crosslinked polyethylene
Number of subjects: 171
Study 23993403 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel Ag
Number of subjects: 20
Study 23993403 — intervention group
Group type: COMPARATOR
Intervention: Alginate Silver
Number of subjects: 20
Study 22283110 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat elimination diet after confirmation of wheat allergy
Number of subjects: 179
Study 22283110 — intervention group
Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenge test with wheat flour
Number of subjects: 179
Study 19415745 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 (rs4917623) heterozygote carriers
Number of subjects: 1067
Study 19415745 — intervention group
Group type: EXPERIMENTAL
Intervention: AhR (rs2066853) heterozygote carriers
Number of subjects: 1067
Study 19415745 — intervention group
Group type: EXPERIMENTAL
Intervention: ERRG (rs1857407) heterozygote carriers
Number of subjects: 1067
Study 19415745 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 (rs762551) homozygote carriers
Number of subjects: 1067
Study 19415745 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 (rs4917623) homozygote carriers
Number of subjects: 1067
Study 19415745 — intervention group
Group type: EXPERIMENTAL
Intervention: ERRG (rs945453) homozygote carriers
Number of subjects: 1067
Study 17324283 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach including contracting, 'Problem Solving Treatment', antidepressant algorithm, and manual-guided self-help
Number of subjects: 126
Study 17324283 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 126
Study 17324283 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach
Number of subjects: 126
Study 15607068 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes requested by RECs regarding the Patient Information Sheet (PIS)
Number of subjects: 187
Study 15607068 — intervention group
Group type: EXPERIMENTAL
Intervention: PIS-related features and type of changes requested
Number of subjects: 187
Study 15607068 — intervention group
Group type: EXPERIMENTAL
Intervention: General content and quality of the PIS
Number of subjects: 187